MedTech Dive October 17, 2025
The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology.
Dive Brief:
- HistoSonics said Thursday that it has raised $250 million to fund the commercial and clinical expansion of its cancer treatment technology.
- Investors that acquired HistoSonics in August joined with other backers to provide the money. Supporters in the latest funding round include Bezos Expeditions and Thiel Bio.
- HistoSonics will use the money to move into new global markets while developing the platform for use in additional clinical indications.
Dive Insight:
HistoSonics’ Edison system uses sound waves to destroy tumors. Backed by Johnson & Johnson, the company received de novo clearance for the device two...
Today's Sponsors
Today's Sponsor